1. According to the Magnesium 2,000 program; 2. Verheye S. Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry. Presented at: TCT; September 25, 2019; San Francisco, USA. NCT02817802; (n = 2,054; 1,075 patients presented); Target Lesion Failure (TLF) is defind as a composite of Cardiac Death, Target-Vessel Myocardial Infarction (TV-MI), Clinically-Driven Target Lesion Revascularization (CD-TLR) and emergent CABG.
Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
Magmaris is currently not available in the US.
© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.